Galvin Roy 4

What Happened

• Galvin Roy, EVP and Chief Commercial Officer of Haemonetics Corporation (HAE), was granted 27,535 restricted stock units (RSUs) on May 15, 2026 (reported on Form 4 filed May 19, 2026). In connection with the vesting of previously reported RSUs, 879 shares were withheld to cover tax obligations at a price of $56.29 per share, totaling $49,479.
• The 27,535 securities are RSUs (contingent rights to one share each) rather than open-market purchases or immediate sales.

Key Details

• Transaction date: May 15, 2026; Form 4 filed: May 19, 2026 (timely filing).
• Withheld shares: 879 shares at $56.29/share = $49,479 (tax withholding; transaction code F).
• Award/grant: 27,535 RSUs (transaction code A); no per-share price reported for the grant.
• Shares owned after transaction: Not specified in the Form 4 provided.
• Notable footnotes: the reported amounts include unvested RSUs previously reported and 415 shares acquired under the Haemonetics Employee Stock Purchase Plan on April 30, 2026. RSUs vest 40% on the first anniversary, 40% on the second, and 20% on the third; each RSU converts to one share when vested.

Context

• RSU grants are compensation awards that vest over time; they are not immediate cash purchases and generally indicate long-term compensation rather than an immediate bullish market bet. The 879-share transfer was a routine tax-withholding event tied to RSU vesting (code F), not an open-market sale.